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1. INTRODUCTION {#jcla23229-sec-0005}
===============

Type 2 diabetes mellitus (T2DM) is associated with compromised health‐related quality of life[1](#jcla23229-bib-0001){ref-type="ref"} and premature death from vascular disease and several types of cancers.[2](#jcla23229-bib-0002){ref-type="ref"}

Insulin resistance is the earliest feature in the development of T2DM. Insulin resistance is induced by obesity, inflammation,[3](#jcla23229-bib-0003){ref-type="ref"} and low physical activity.[4](#jcla23229-bib-0004){ref-type="ref"}

Conversely, physical activity accompanied by weight loss leads to improvement in insulin sensitivity.[5](#jcla23229-bib-0005){ref-type="ref"}

The positive energy balance leads to body weight gain.[6](#jcla23229-bib-0006){ref-type="ref"} Obese adipose tissue is characterized by the presence of leukocytes with subsequent increased production of pro‐inflammatory cytokines leading to chronic subclinical inflammation.[7](#jcla23229-bib-0007){ref-type="ref"} The insulin receptor signal transduction is inhibited by inflammatory cytokines, which leads to the development of insulin resistance.[8](#jcla23229-bib-0008){ref-type="ref"}

The body mass index (BMI) is the most common index of the amount of whole‐body adipose tissue. Mainly, the visceral adipose tissue induces the chronic inflammation and development of T2DM.[9](#jcla23229-bib-0009){ref-type="ref"} Recently, a relative fat mass (RFM) was suggested as a better estimator of whole‐body fat percentage.[10](#jcla23229-bib-0010){ref-type="ref"} Lack of physical activity is associated with abdominal adiposity and low‐grade inflammation independent of BMI.[11](#jcla23229-bib-0011){ref-type="ref"}

Simple obesity increases the risk of chronic kidney disease (CKD) independently of other risk factors.[12](#jcla23229-bib-0012){ref-type="ref"} CKD is a frequent long‐term complication in elderly T2DM patients. Current clinical practice uses mainly the estimated glomerular filtration rate from serum creatinine (eGFRcrea) for the estimation of GFR.[13](#jcla23229-bib-0013){ref-type="ref"} However, older people may lose their muscle mass due to chronic conditions, which leads to overestimation of true GFR.

Cystatin C is an alternative marker of GFR, which does not depend on muscle mass[14](#jcla23229-bib-0014){ref-type="ref"} but some non‐GFR factors also affect its serum concentration.[15](#jcla23229-bib-0015){ref-type="ref"} Cystatin C has the ability to select people at higher cardiometabolic risk compared to creatinine.[16](#jcla23229-bib-0016){ref-type="ref"} T2DM is also associated with nonalcoholic fatty liver disease (NAFLD).[17](#jcla23229-bib-0017){ref-type="ref"}

However, RFM is a new estimator of fat mass and the associations between RFM, eGFR, and chronic inflammation are unclear in T2DM patients. Therefore, we performed the study to analyze the degree of obesity and its associations with age, gender, inflammation, the estimated glomerular filtration rate (eGFR), and liver function in T2DM patients.

2. MATERIALS AND METHODS {#jcla23229-sec-0006}
========================

2.1. Patients {#jcla23229-sec-0007}
-------------

This is a retrospective cross‐sectional observational study. A total of 874 Caucasian consecutive patients with T2DM from outpatient diabetic clinic in Zlín (Czech Republic) were included in the study. The median (range) of their age was 68 (19‐97) years. There were 474 males and 400 females. Data were collected from September 2018 to March 2019.

Waist circumference was measured by nurse as the widest waist circumference. All anthropometric parameters were measured by nurse on the same day as blood sampling.

The anthropometric parameters were calculated according to the following equations: RFM (for males) = 64 − (20 × (height/waist))RFM (for females) = 76 − (20 × (height/waist))

Height and waist circumference were measured in centimeters. BMI = weight/height^2^

Obesity was defined as BMI of at least 30 kg/m^2^ for both genders or RFM ≥ 33.9% for women and ≥ 22.8% for men.[10](#jcla23229-bib-0010){ref-type="ref"}

2.2. Laboratory methods {#jcla23229-sec-0008}
-----------------------

Fasting blood samples were collected by nurse using 6 mL VACUETTE^®^ red top tubes with clot activator (Greiner Bio‐One GmbH, Kremsmünster, Austria).

Serum creatinine was measured by the enzymatic method traceable to international standard reference material of NIST SRM 967.[18](#jcla23229-bib-0018){ref-type="ref"}

Cystatin C was measured by standardized immunoturbidimetric assay traceable to European Reference Material ERM‐DA471/IFCC.[19](#jcla23229-bib-0019){ref-type="ref"}

The CKD‐EPI equations were used for the estimation of GFR.[20](#jcla23229-bib-0020){ref-type="ref"}, [21](#jcla23229-bib-0021){ref-type="ref"} The CKD was defined as the eGFR value below 60 mL/min/1.73 m^2^.[22](#jcla23229-bib-0022){ref-type="ref"}

The hsCRP method used six‐point calibration traceable to European Reference Material ERM‐DA472/IFCC. The systemic chronic inflammation was defined as serum hsCRP levels of ≥2.0 mg/L.[23](#jcla23229-bib-0023){ref-type="ref"}

The alanine aminotransferase activity (ALT) was measured in the presence of pyridoxal‐5‐phosphate. The kinetic method uses coupled enzyme reaction, and the rate of nicotinamide adenine dinucleotide phosphate (NADPH) consumption is measured at 340 nm.

2.3. Statistical tests {#jcla23229-sec-0009}
----------------------

The D\'Agostino‐Pearson test was used for normal distribution assessment. The normal distribution was rejected. We used non‐parametric tests for statistical testing. The level of significance was defined as a *P* value below.05. The Spearman rank correlation coefficient was used for association evaluation. Mann‐Whitney test for independent samples was employed for comparison of medians.

The analysis of data was performed by R statistical programming language version 3.6.0 (R Core Team).

3. RESULTS {#jcla23229-sec-0010}
==========

The median, interquartile range (IQR) of RFM in females was higher than that in males (44.8 (42.3‐47.2) % vs 31.3 (28.8‐34.1) %, respectively; *P* \< .0001). The median (IQR) of BMI in females was no higher than that in males (30 (27‐34) kg/m^2^ vs 30 (27‐34), respectively; *P* = .5152). The obesity prevalence was 99% in males and 98% in females according to RFM. BMI recognized obesity in 51% males and 53% females. RFM was positively associated with hsCRP in both males (*r~s~* = .296, *P* \< .0001) and females (*r~s~* = .445, *P* \< .0001). ALT was positively correlated with eGFRcys in both males (*r~s~* = .379, *P* \< .0001) and females (*r~s~* = .308, *P* \< .0001).

The clinical characteristics and sex differences are shown in Table [1](#jcla23229-tbl-0001){ref-type="table"}.

###### 

The clinical characteristics and sex differences

  Variable                      Males (n = 474) Median (IQR)   Females (n = 400) Median (IQR)   *P*
  ----------------------------- ------------------------------ -------------------------------- ---------
  Age (y)                       66 (58‐72)                     71 (63‐79)                       \<.0001
  RFM (%)                       31.3 (28.8‐34.1)               44.8 (42.3‐47.2)                 \<.0001
  BMI (kg/m^2^)                 30 (27‐34)                     30 (27‐34)                       .5152
  eGFRcrea (mL/min/1.73 m^2^)   79 (62‐92)                     71 (54‐87)                       .0017
  eGFRcys (mL/min/1.73 m^2^)    77 (61‐95)                     65 (51‐84)                       \<.0001
  hsCRP (mg/L)                  1.9 (1.0‐4.2)                  2.4 (1.0‐5.4)                    .0265
  ALT (ukat/L)                  0.48 (0.34‐0.67)               0.35 (0.26‐0.49)                 \<.0001

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; eGFRcrea, estimated glomerular filtration rate from serum creatinine; eGFRcys, estimated glomerular filtration rate from serum cystatin C; hsCRP, high‐sensitive C‐reactive protein; RFM: relative fat mass.
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RFM and BMI in males and females are displayed in Figure [1](#jcla23229-fig-0001){ref-type="fig"}.

![The relative fat mass (RFM) and body mass index (BMI) in males and females](JCLA-34-e23229-g001){#jcla23229-fig-0001}

The associations between markers of obesity, age, eGFR, chronic inflammation, and ALT for all patients are displayed in Table [2](#jcla23229-tbl-0002){ref-type="table"}.

###### 

Spearman\'s rank correlation coefficients between markers of obesity, age, eGFR, chronic inflammation, and ALT

+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
|       | Sex                                                        | RFM                                                        | BMI                                                        | Age                                                        | eGFR crea                                                  | eGFR cys                                                   | hsCRP                                                      | ALT                                                        |
+=======+============================================================+============================================================+============================================================+============================================================+============================================================+============================================================+============================================================+============================================================+
| RFM   | M                                                          |                                                            | **0.851** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −0.068                                                     | 0.044                                                      | −**0.114**                                                 | **0.296** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | 0.060                                                      |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     |                                                            | **0.804** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −0.001                                                     | −0.049                                                     | −**0.193** [**\***](#jcla23229-note-0004){ref-type="fn"}   | **0.445** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | 0.008                                                      |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| BMI   | M                                                          | **0.851** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            | −**0.282** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.142**                                                  | 0.031                                                      | **0.284** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | **0.178** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | **0.804** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            | −**0.203** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | 0.072                                                      | −0.048                                                     | **0.470** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | 0.092                                                      |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| Age   | M                                                          | −0.068                                                     | −**0.282** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |                                                            | −**0.598** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | −**0.577** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | −0.082                                                     | −**0.474** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | −0.001                                                     | −**0.203** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |                                                            | −**0.668** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | −**0.681** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | −**0.140**                                                 | −**0.340**                                                 |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| eGFR  | M                                                          | 0.044                                                      | **0.142**                                                  | −**0.598** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |                                                            | **0.762** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −0.020                                                     | **0.336** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |
|       |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| crea  |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | −0.049                                                     | 0.072                                                      | −**0.668** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |                                                            | **0.845** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | 0.060                                                      | **0.233** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| eGFR  | M                                                          | **−0.114**                                                 | 0.031                                                      | −**0.577** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.762** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            | −**0.208** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.379** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |
|       |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
| cys   |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | **−0.193** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | −0.048                                                     | −**0.681** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.845** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            | −0.083                                                     | **0.308** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| hsCRP | M                                                          | **0.296** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | **0.284** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −0.082                                                     | −0.020                                                     | −**0.208** [**\*\***](#jcla23229-note-0005){ref-type="fn"} |                                                            | −0.033                                                     |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | **0.445** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | **0.470** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −**0.140**                                                 | 0.060                                                      | −0.083                                                     |                                                            | 0.000                                                      |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| ALT   | M                                                          | 0.060                                                      | **0.178** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −**0.474** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.336** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | **0.379** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | −0.033                                                     |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+
| F     | 0.008                                                      | 0.092                                                      | −**0.340** [**\*\***](#jcla23229-note-0005){ref-type="fn"} | **0.233** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | **0.308** [**\*\***](#jcla23229-note-0005){ref-type="fn"}  | 0.000                                                      |                                                            |                                                            |
+-------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+------------------------------------------------------------+

Abbreviations: ALT, Alanine aminotransferase; BMI, Body mass index; eGFR crea, estimated glomerular filtration rate from serum creatinine; eGFR cys, estimated glomerular filtration rate from serum cystatin C; hsCRP, high‐sensitive C‐reactive protein; RFM: relative fat mass.

*P* \< .01 (bold).

*P* \< .001 (bold).

*P* \< .0001 (bold); 474 males, 400 females.
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The prevalence of obesity, CKD, and chronic inflammation in T2DM patients are shown in Table [3](#jcla23229-tbl-0003){ref-type="table"}.

###### 

The prevalence of obesity, CKD, and chronic inflammation in T2DM patients

                                  Males (n = 474)     Females (n = 400)   *P*
  ------------------------------- ------------------- ------------------- -------
  Obesity by RFM                  469 cases (98.9%)   392 cases (98.0%)   .921
  Obesity by BMI                  242 cases (51.1%)   212 cases (53.0%)   .747
  CKD according to eGFRcrea       100 cases (21.1%)   132 cases (33.0%)   .090
  CKD according to eGFRcys        105 cases (22.2%)   155 cases (38.8%)   .0001
  Chronic inflammation by hsCRP   233 cases (49.2%)   221 cases (55.3%)   .313

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; eGFRcrea, estimated glomerular filtration rate from serum creatinine; eGFRcys, estimated glomerular filtration rate from serum cystatin C; hsCRP, high‐sensitive C‐reactive protein; RFM, relative fat mass.

John Wiley & Sons, Ltd

4. DISCUSSION {#jcla23229-sec-0011}
=============

We found much higher prevalence of obesity by RFM compared to BMI in T2DM patients. The RFM was higher in females compared to males. The positive association with hsCRP was observed for both RFM and BMI.

Batsis et al analyzed results from National Health and Nutrition Examination Survey (NHANES) performed between 1999 and 2004, and showed lower obesity rate according to BMI compared to body fat mass measurement by dual‐energy X‐ray absorptiometry. Participants of the NHANES study were recruited from general population, and obesity limits of body fat mass amount were defined at 25% for males and 35% for females. In the NHANES study, mean male percentage body fat was 30.6% at ages 60‐79 years. Females in the same age range had mean percentage body fat of 42.6%.[24](#jcla23229-bib-0024){ref-type="ref"} Our study confirmed lower BMI‐marked obesity rate in both sexes. These results support current knowledge on pathophysiological development of T2DM. Fat mass promotes both insulin resistance and chronic inflammation development. The diagnosis of T2DM is at the end of these interrelated pathophysiological processes. It may be reason that nearly, all T2DM patients were obese by RFM.

Schorr et al demonstrated differences in body composition between men and women. Women had higher percentage of fat mass, and men had larger visceral adipose tissue, which means higher cardiometabolic risk for men.[25](#jcla23229-bib-0025){ref-type="ref"} It is consistent with our RFM results, which are significantly different between males and females.

Park et al reported positive association between obesity and hsCRP.[26](#jcla23229-bib-0026){ref-type="ref"} It is consistent with our results.

Leung et al found higher hsCRP in people with central obesity compared to subjects without central obesity. Waist circumference was measured at the widest point of the waist.[27](#jcla23229-bib-0027){ref-type="ref"} It supports our results of increased hsCRP in patients with higher results of both RFM and BMI.

Wang et al showed in the meta‐analysis involving 22 cohorts, with a total of 40 735 participants and 5,753 cases, that elevated CRP levels were significantly associated with increased risk of T2DM.[28](#jcla23229-bib-0028){ref-type="ref"} This interrelationship between T2DM and inflammation may be in accordance with our finding of high proportion of elevated levels of hsCRP in our cohort of patients with overt T2DM.

Dias et al reported that the GFR was decreasing with increasing mean values of nutritional indicators of abdominal obesity regardless of sex.[29](#jcla23229-bib-0029){ref-type="ref"} Our study found inverse trends in association between RFM and eGFRcys in females (*r~s~* = −.193, *P* \< .0001) and in males (*r~s~* = −.114, *P* = .01).

Wang et al performed meta‐analysis of 21 studies, which concluded that obesity increases the risk for CKD in the general population, and the association appears to be stronger in women than in men. Overweight people have a 40% higher risk for CKD.[30](#jcla23229-bib-0030){ref-type="ref"} Our cohort of T2DM patients had high proportion of CKD patients according to both eGFRcrea and eGFRcys. The negative correlation between RFM and eGFRcys was also higher in women compared to men.

Adiga et al reported positive correlation between eGFR and ALT in T2DM patients.[31](#jcla23229-bib-0031){ref-type="ref"} The positive association between ALT and both eGFRcrea and eGFRcys in our patients is in accordance with this study.

The development of T2DM is much more complex. Qiu et al reported that blood microbiome may play a role in the development of T2DM.[32](#jcla23229-bib-0032){ref-type="ref"} Ghasemi et al showed that genetic polymorphism has a role in T2DM development.[33](#jcla23229-bib-0033){ref-type="ref"} Peng et al demonstrated that serum carbohydrate antigen 153 negatively correlates with renal function in T2DM patients.[34](#jcla23229-bib-0034){ref-type="ref"} We did not include these laboratory tests in our study. The limitations of this study are the absence of the reference methods for the determination of body fat percentage and GFR.

In summary, the RFM equation leads to much higher obesity prevalence compared to BMI. This knowledge of body composition should impact the clinical practice. Women have higher RFM compared to men. The positive association with hsCRP was observed for both RFM and BMI. The kidney function was positively correlated with serum ALT concentration.
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